DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9,675,592 B2 Daum Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9,675,592 B2 Daum Et Al USOO9675592B2 (12) United States Patent (10) Patent No.: US 9,675,592 B2 Daum et al. (45) Date of Patent: Jun. 13, 2017 (54) METHODS AND COMPOSITIONS FOR (52) U.S. Cl. BACTERIA INFECTIONS CPC .......... A61K 31/431 (2013.01); A61K 9/0019 (71) Applicants: THE UNIVERSITY OF CHICAGO, ( 2013.01);) A6IK3I/05 ((2013.01): ) Chicago, IL (US): THE BOARD OF (Continued) REGENTS OF THE UNIVERSITY (58) Field of Classification Search OF ILLINOIS, Urbana, IL (US) CPC ... A61K 3 1/519; A61K 31/427; A61K 31/428; A61K 31/446 (72) Inventors: Robert S. Daum, Chicago, IL (US); Continued Susan Boyle-Vavra, Chicago, IL (US); (Continued) Michael E. Johnson, Urbana, IL (US) (56) References Cited (73) Assignees: The University of Chicago, Chicago, U.S. PATENT DOCUMENTS IL (US); The Board of Regents of the University of Illinois, Urbana, IL (US) 5,776,919 A 7, 1998 Sukigara et al. ............. 514, 161 2010.0029597 A1 2/2010 Cottarel et al. ............... 514,154 (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U.S.C. 154(b) by 0 days. WO WO 2012151474 11 2012 WO WO 2014O71198 5, 2014 (21) Appl. No.: 14/776,965 (22) PCT Filed: Mar. 14, 2014 OTHER PUBLICATIONS (86). PCT No.: PCT/US2014/029237 Berge, et al., J Pharmaceutical Sci. 66(1):1-19, 1977. S 371 (c)(1)C s (Continued) (2) Date: Sep. 15, 2015 Primary Examiner — Shengjun Wang (87) PCT Pub. No.: WO2014/144710 Storney Agent, or Firm — Norton Rose Fulbright PCT Pub. Date: Sep. 18, 2014 (57) ABSTRACT (65) Prior Publication Data Compositions and methods are provided for treating or US 2016/0120852 A1 May 5, 2016 inhibiting a bacterial infection involving at least one anti Related U.S. Application Data biotic and a compound that potentiates the antibiotic activity of the antibiotic. In certain embodiments the antibiotic is a (60) Provisional application No. 61/789,716, filed on Mar. beta lactam. In further embodiments, the antibiotic is oxa 15, 2013. cillin. In additional embodiments, the potentiating com pound is an inhibitor of VraSR operon expression. In specific (51) Int. Cl. embodiments, the bacterial infection involves an antibiotic A6 IK 3/44 3.08: resistant bacteria. A 6LX 3/59 2006.O1 (Continued) 20 Claims, 6 Drawing Sheets 0.5 (ciacin)2 4mg. 5 US 9,675,592 B2 Page 2 (51) Int. Cl. 31/519 (2013.01); A61K3I/5377 (2013.01); A6 IK3I/53 (2006.01) A61K 31/7036 (2013.01); A61K 45/06 A6 IK 3/425 (2006.01) (2013.01) A6 IK 3L/45 (2006.01) (58) Field of Classification Search A6 IK3I/05 (2006.01) USPC ......... 514/736, 342, 260.1, 262.1, 367, 371, A6 IK 3/43 (2006.01) 514/245, 394, 259.31, 403,364 A6 IK 3/43 (2006.01) See application file for complete search history. A6 IK 45/06 (2006.01) (56) References Cited A6 IK 9/00 (2006.01) A6 IK 3/46 (2006.01) A6 IK 3/42.45 (2006.01) OTHER PUBLICATIONS A6 IK 3/428 (2006.01) Boyle-Vavra, et al., Antimicrob Agents Chemother: 57(1):83-95, A6 IK 3/4439 (2006.01) 2013. A6 IK 3L/454 (2006.01) Boyle-Vavra, et al., FEMS Microbiol Lett. 262(2):163-171, 2006. A 6LX 3L/24709 (2006.01) EllisO, et al., el, Antimicro C, teis Cleppother:ES' SS: Z 2011 A6 IK 3/4725 (2006.01) Livak & Schmittgen, St. 25(4):402-408, 2001. A6 IK 3/496 (2006.01) Montgomery, et al., J Infect Dis. 198(4):561-570, 2008. A 6LX 3/5.377 (2006.01) Rohner et al. “Synergistic Effect of Quinolones and Oxacillin on A6 IK3I/7036 (2006.01) Methicillin-Resistant Staphylococcus Species' Antimicrobial (52) U.S. Cl. Agents and Chemotherapy, 33(12): 2037-2041, 1989. CPC .......... A61K 31/416 (2013.01); A61K 31/428 Yin, et al., Antimicrobial Agents Chemother: 50(1):336-343, 2006. International Search Report and Written Opinion issued in PCT/ (2013.01); A61K 31/4245 (2013.01); A61 K US2014/029237, mailed on Aug. 11, 2014. 31/4439 (2013.01); A61K 31/454 (2013.01); Extended European Search Report for EP 14764384.5, mailed Oct. A6 IK3I/4709 (2013.01); A61K 31/4725 12, 2016. (2013.01); A61 K3I/496 (2013.01); A61 K Reynolds et al., Tuberculosis 92 (2012) 72-83. U.S. Patent Jun. 13, 2017 Sheet 1 of 6 US 9,675,592 B2 ! ------------------- O O.5 1 2 3 4. 5 6 6 18 Oxacillin) mg/L. time (hours * Ill 1 Oxacillin2 3 4mg/L. 5 6 F.G. 1 A-1C U.S. Patent Jun. 13, 2017 Sheet 2 of 6 US 9,675,592 B2 A 5 | vasr VraSR wraSR active 20 inactive uncertain average 15 average 10 as re-- """ g 20 3. uninhibited ' 15 og average s - 2 SD aWeaCe g 10 5 5 - 2 SD O --------- -----------T- DDDD • F- s -Y N) () a cu C N CO CO - a -a - a -a -a -a -a -a -a -a N) N. N. N. N. N. d - a Nad co -na cu o N Co co o -a n) ca) a U. ODs bin number FIG. 2A-2B U.S. Patent Jun. 13, 2017 Sheet 3 of 6 US 9,675,592 B2 1 2 3 4 5 6 7 His-VraS-C VraS-C U.S. Patent Jun. 13, 2017 Sheet 4 of 6 US 9,675,592 B2 3OO 2 250 200 150 O 10 20 30 40 (F2645-0188 (uM) FIG. 4 U.S. Patent Jun. 13, 2017 Sheet 5 of 6 US 9,675,592 B2 U.S. Patent Jun. 13, 2017 Sheet 6 of 6 US 9,675,592 B2 Y a . 3 3 3. ful 3. O D.5 2 4 8 6. 32 f 3 2 4 B 16 32 F2645-0.188 F5882-3050 V 2 4. - 8 - 16 - 32 64 O 0,5 1 2 4 8 16 32 FO020-1560 F1813-0712 O 2 4 8 16 32 64 O 0.5 1 2 4 8 16 32 F2703-0396 O F2619-0556 O 2 0.25 4 0.5 8 1 16 32 64 Growth in MBC (3-log Min conc to broth after 24 hr reduction in E reduce Ox MIC CFU) by 32x FIG. 6 US 9,675,592 B2 1. 2 METHODS AND COMPOSITIONS FOR 2,5-dichlorophenyl, 2,5-dichlorothiophen-3-yl, 2,6-difluo BACTERIA INFECTIONS rophenyl, 2-bromothiophen-5-yl, 2-chlorothiophen-5-yl, 2-naphthyl 2-phenoxyphenyl, 2-phenylduinolin-4-yl, 3-(2- CROSS-REFERENCE TO RELATED chlorophenyl)-5-methylisoxazol-4-yl, 3,4,5-trimethoxyphe APPLICATIONS nyl, 3,5-dichlorophenyl, 3,5-dimethoxyphenyl, 3-bro mophenyl, 3-chlorobenzobthiophen-2-yl, 3-chlorophenyl, This application is a national phase application under 35 3-fluorophenyl, 3-methoxyphenyl, 3-n-butoxyphenyl, U.S.C. 371 of International Application No. PCT/US2014/ 3-phenoxyphenyl, 3-tolyl, 3-trifluoromethylphenyl, 4-(2,6- 09237, filed on Mar. 14, 2014, which claims the benefit of dimethylmorpholinosulfonyl)phenyl, 4-(2-ethylpiperidin-1- priority of U.S. Provisional Patent Application No. 61/789, 10 ylsulfonyl)phenyl, 4-(2-methylpiperidin-1-ylsulfonyl)phe 716, filed on Mar. 15, 2013. The entire contents of each of nyl, 4-(2-phenylduinoline), 4-(3,4-dihydroisoquinolin-2 the above-referenced disclosures are specifically incorpo (1H)-ylsulfonyl)phenyl, 4-(3,4-(dihydroquinolin-1 (2H)- rated herein by reference without disclaimer. ylsulfonyl)phenyl, 4-(3,5-dimethylpiperidin-1-ylsulfonyl) phenyl, 4-(4,4-dimethyloxazolidin-3-ylsulfonyl)phenyl, BACKGROUND OF THE INVENTION 15 4-(morpholinosulfonyl)phenyl, 4-(N,N-diallylsulfamoyl) 1. Field of the Invention phenyl, 4-(N,N-diethylsulfamoyl)phenyl, 4-(N,N-diisobu The present invention relates generally to the field of tylsulfamoyl)phenyl, 4-(N,N-dimethylsulfamoyl)phenyl, medicine. More particularly, it concerns the use of chemical 4-(N-ethyl-N-benzylsulfamoyl)phenyl, 4-(N-ethyl-N-n-bu compounds that inhibit the VraSR operon and potentiate the tyl-sulfamoyl)phenyl, 4-(N-ethyl-N-phenylsulfamoyl)phe action of antibiotics. nyl, 4-(N-isopropyl-N-benzylsulfamoyl)phenyl 4-(N- 2. Description of Related Art methyl-N-benzylsulfamoyl)phenyl, 4-(N-methyl-N- Staphylococcus aureus is a well-adapted human parasite cyclohexylsulfamoyl)phenyl, 4-(N-methyl-N-n- that is both a commensal and an important pathogen. It is butylsulfamoyl)phenyl, 4-(N-methyl-N-phenylsulfamoyl) responsible for a wide variety of infectious diseases that 25 phenyl, 4-(piperidin-1-ylsulfonyl)phenyl, 4-(pyrrolidin-1- range from minor skin abscesses to severe infections and ylsulfonyl)phenyl, 4-benzoylphenyl, 4-benzylphenyl, toxinoses requiring hospitalization. Staphylococcus aureus 4-biphenyl, 4-chlorophenyl, 4-diphenyl, 4-ethoxyphenyl, strains resistant to nearly all beta-lactams, so-called methi 4-fluorophenyl, 4-phenoxyphenyl, 4-tert-butylphenyl, cillin-resistant Staphylococcus aureus (MRSA), are a lead 30 7-methoxybenzofuran-2-yl, benzodthiazol-2-yl, benzod ing cause of healthcare associated and, since the 1990s, thiazol-4-yl, benzodthiazol-6-yl, benzofuran-2-yl, diphe community-associated infection. An epidemic of MRSA nylmethyl, methyl-4-benzoate, phenyl, or thiophen-2-yl, and infections has enhanced the urgency to identify alternative R may be 1,2,3,4-tetrahydronaphthalen-6-yl, 2-(methyl antibacterial agents for Successful treatment. Unfortunately, thio)phenyl, 2,3-dihydro-1,4-dioxin-2-yl, 2,3-dihydrobenzo this need comes at a time when the industry-driven pipeline 35 b1,4-dioxin-2-yl, 2,3-dihydrobenzob 1,4-dioxin-6-yl, for antibacterial development has slowed. 2,4-dichlorophenyl, 2,4-dimethoxyphenyl, 2,4-dimethyl phenyl, 2,5-dichlorophenyl, 2,5-dichlorothiophen-3-yl 2.5- SUMMARY OF THE INVENTION dimethylphenyl, 2-bromothiophen-2-yl, 2-chlorophenyl, 2-chlorothiophen-2-yl, 2-chlorothiophen-5-yl, 2-furanyl, Methods and compositions are provided for inhibiting, 40 2-methoxyphenyl, 2-pyridinyl, 3-(methylthio)phenyl, 3,4,5- preventing, or treating a bacterial infection, particularly trimethoxyphenyl, 3,4-dimethoxyphenyl, 3,4-dimethylphe bacteria that rely on a VraSR operon for signal transduction.
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,662.400 B2 Smith Et Al
    USOO9662400B2 (12) United States Patent (10) Patent No.: US 9,662.400 B2 Smith et al. (45) Date of Patent: *May 30, 2017 (54) METHODS FOR PRODUCING A (2013.01); C08B 37/003 (2013.01); C08L 5/08 BODEGRADABLE CHITOSAN (2013.01); A6 IK 38/00 (2013.01); A61 L COMPOSITION AND USES THEREOF 2300/404 (2013.01) (58) Field of Classification Search (71) Applicant: University of Memphis Research CPC ...... A61K 47/36; A61K 31/00; A61K 9/7007; Foundation, Memphis, TN (US) A61K 9/0024; A61 L 15/28: A61L 27/20; A61L 27/58: A61L 31/042; C08B 37/003 (72) Inventors: James Keaton Smith, Memphis, TN USPC ................................ 514/23, 40, 777; 536/20 (US); Ashley C. Parker, Memphis, TN See application file for complete search history. (US); Jessica A. Jennings, Memphis, (56) References Cited TN (US); Benjamin T. Reves, Memphis, TN (US); Warren O. U.S. PATENT DOCUMENTS Haggard, Bartlett, TN (US) 4,895,724. A * 1/1990 Cardinal .............. A61K9/0024 424,278.1 (73) Assignee: The University of Memphis Research 5,541,233 A 7/1996 Roenigk Foundation, Memphis, TN (US) 5,958,443 A 9/1999 Viegas et al. 6,699,287 B2 3/2004 Son et al. (*) Notice: Subject to any disclaimer, the term of this 6,989,157 B2 1/2006 Gillis et al. patent is extended or adjusted under 35 7,371.403 B2 5/2008 McCarthy et al. 2003, OO15825 A1 1/2003 Sugie et al. U.S.C. 154(b) by 0 days. 2003/0206958 A1 11/2003 Cattaneo et al.
    [Show full text]
  • Derivatives of Clavulanic Acid, Process for Their Preparation And
    Europaisches Patentamt © ê European Patent Office © Publication number: 0 003 254 Office européen des brevets Bl © EUROPEAN PATENT SPECIFICATION (45) Date of publication of patent spécification: 28.03.84 © Int. ci.3: C 07 D 498/04, A 61 K 31/42, @ Application number: 78300762.8 A 61 K 31/43, @ Date offiling: 07.12.78 A 61 K 31/545 //(C07D498/04, 263/00, 205/00), (A6 1 K3 1 /43, 3 1/42), (A61K3 1/545, 31/42) (54) Derivatives of clavulanic acid, process for their préparation and compositions containing them. (§) Priority: 26.01 .78 GB 312978 @ Proprietor: BEECHAM GROUP PLC Beecham House Great West Road Brentford Middlesex (GB) (43) Date of publication of application: 08.08.79 Bulletin 79/1 6 @ Inventor: Gasson, Brian Charles 9, Clarence Walk (45) Publication of the grant of the patent: Redhill Surrey (GB) 28.03.84 Bulletin 84/13 © Représentative: Hesketh, Alan, Dr. et al, (84) Designated Contracting States: European Patent Attorney Beecham BE CH DEFRGBITNL Pharmaceuticals Great Burgh Yew Tree Bottom Road Epsom, Surrey, KT18 5XQ (GB) (56) Références cited: BE - A - 847 046 The file contains technical information submitted after the application was filed and not included in this spécification Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid.
    [Show full text]
  • United States Patent ( 10 ) Patent No.: US 10,561,6759 B2 Griffith Et Al
    US010561675B2 United States Patent ( 10 ) Patent No.: US 10,561,6759 B2 Griffith et al. (45 ) Date of Patent : * Feb . 18 , 2020 (54 ) CYCLIC BORONIC ACID ESTER ( 58 ) Field of Classification Search DERIVATIVES AND THERAPEUTIC USES CPC A61K 31/69 ; A61K 31/396 ; A61K 31/40 ; THEREOF A61K 31/419677 (71 ) Applicant: Rempex Pharmaceuticals , Inc. , (Continued ) Lincolnshire , IL (US ) (56 ) References Cited (72 ) Inventors : David C. Griffith , San Marcos, CA (US ) ; Michael N. Dudley , San Diego , U.S. PATENT DOCUMENTS CA (US ) ; Olga Rodny , Mill Valley , CA 4,194,047 A 3/1980 Christensen et al . ( US ) 4,260,543 A 4/1981 Miller ( 73 ) Assignee : REMPEX PHARMACEUTICALS , ( Continued ) INC . , Lincolnshire , IL (US ) FOREIGN PATENT DOCUMENTS ( * ) Notice : Subject to any disclaimer, the term of this EP 1550657 A1 7/2005 patent is extended or adjusted under 35 JP 2003-229277 A 8/2003 U.S.C. 154 ( b ) by 1129 days. (Continued ) This patent is subject to a terminal dis claimer . OTHER PUBLICATIONS Abdel -Magid et al. , “ Reductive Amination ofAldehydes and Ketones ( 21) Appl. No .: 13 /843,579 with Sodium Triacetoxyborohydride: Studies on Direct and Indirect Reductive Amination Procedures ” , J Org Chem . ( 1996 )61 ( 11 ): 3849 ( 22 ) Filed : Mar. 15 , 2013 3862 . (65 ) Prior Publication Data (Continued ) US 2013/0331355 A1 Dec. 12 , 2013 Primary Examiner — Shengjun Wang Related U.S. Application Data (74 ) Attorney, Agent, or Firm — Wilmer Cutler Pickering (60 ) Provisional application No.61 / 656,452 , filed on Jun . Hale and Dorr LLP 6 , 2012 (57 ) ABSTRACT (51 ) Int. Ci. A61K 31/69 ( 2006.01) Method of treating or ameliorating a bacterial infection A61K 31/00 ( 2006.01 ) comprising administering a composition comprising a cyclic (Continued ) boronic acid ester compound in combination with a car ( 52 ) U.S.
    [Show full text]
  • AMR Surveillance in Pharma: a Case-Study for Data Sharingauthor by Professor Barry Cookson
    AMR Open Data Initiative AMR Surveillance in Pharma: a case-study for data sharingauthor by Professor Barry Cookson External Consultant to Project eLibrary • Division of Infection and Immunity, Univ. College London ESCMID• Dept. of Microbiology, © St Thomas’ Hospital Background of “90 day Project” Addressed some recommendations of the first Wellcome funded multi-disciplinary workshop (included Pharma Academia & Public Health invitees: 27thauthor July 2017 (post the Davos Declaration): by 1) Review the landscape of existing Pharma AMR programmes, their protocols,eLibrary data standards and sets 2) Develop a "portal" (register/platform) to access currently available AMR Surveillance data ESCMID Important ©to emphasise that this is a COLLABORATION between Pharma and others Overview of Questionnaire Content • General information - including name,author years active, countries, antimicrobials, microorganisms.by • Methodology - including accreditation, methodology for; surveillance, isolate collection, organism identification, breakpointseLibrary used, • Dataset - including data storage methodology, management and how accessed. ESCMID © 13 Company Responses author 7 by 3 3 eLibrary ESCMID © Structure of register Companies can have different ways of referring to their activities: We had to choose a consistent framework. author Companies Companyby 1 Programmes Programme A Programme B eLibrary Antimicrobials 1 2 3 4 5 company’s product comparator company’s product antimicrobials Programmes canESCMID contain multiple studies (e.g. Pfizer has© single
    [Show full text]
  • Comparison Between the Molecular and Crystal Structures of a Benzylpenicillin Ester and Its Corresponding Sulfoxide with Drastically Reduced Biological Activity
    Comparison between the Molecular and Crystal Structures of a Benzylpenicillin Ester and its Corresponding Sulfoxide with Drastically Reduced Biological Activity Harald Labischinski*, Dieter Naumann Robert-Koch-Institut des Bundesgesundheitsamtes, Nordufer 20, D-1000 Berlin (West) 65 Gerhard Barnickel3, Wolfgang Dreißig, Wojciech Gruszecki, Andreas Hofer, and Hans Bradaczek Institut für Kristallographie, Freie Universität Berlin, Takustraße 6, D-1000 Berlin (West) 33 Z. Naturforsch. 42b, 367-375 (1987); received June 30/0ctober 14, 1986 X-Ray, Penicillin G, Penicillin G Sulfoxide, Thiazolidine Ring Conformation, Structure Activity Relationships A comparative X-ray structure determination was performed to elucidate possible conforma- tional differences between penicillins and penicillin sulfoxides. Penicillin-G-acetoxy-methylester and its Iß-oxide were used as model substances, because the only chemical difference between both compounds resides in the thiazolidine ring sulfur oxidation. On the basis of the X-ray data as well as of infrared measurements it is discussed that the drastically reduced biological activity of the penicillin-G-sulfoxide might be related to conformational differences in thiazolidine ring puckering or, even more simply, to the geometric position of the sulfoxide oxygen atom, both of which may hamper the proper reaction of the sulfoxide with its target enzyme(s). Introduction transformation, i.e. no penetration problems nor /3-Lactam antibiotics, although being in therapeut- any destruction by ß-lactamases should occur): First, ical use for more than 40 years, still provide the most the chemical reactivity leading to the acylation of the widely used antibacterial drugs. An enormous target enzyme might be changed or, secondly the amount of chemical modifications of the originally ability for proper interaction with the protein might discovered penicillin G structure has been syn- be affected by conformational factors.
    [Show full text]
  • The Oral Pheneticillin Absorption Test: an Accurate Method to Identify Patients with Inadequate Oral Pheneticillin Absorption
    antibiotics Brief Report The Oral Pheneticillin Absorption Test: An Accurate Method to Identify Patients with Inadequate Oral Pheneticillin Absorption Anneke C. Dijkmans 1,*, Dinemarie M. Kweekel 2, Jaap T. van Dissel 3, Michiel J. van Esdonk 1 , Ingrid M. C. Kamerling 1 and Jacobus Burggraaf 1 1 Centre for Human Drug Research (CHDR), 2333 CL Leiden, The Netherlands 2 Department of Clinical Pharmacy, Leiden University Medical Center (LUMC), 2333 ZA LeidenLeiden, The Netherlands 3 Department of Infectious Diseases, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands * Correspondence: [email protected] Received: 9 July 2019; Accepted: 8 August 2019; Published: 15 August 2019 Abstract: Severe streptococcal infections are commonly treated with intravenous followed by oral penicillin (pheneticillin) therapy. However, switching from iv to oral therapy is complicated by the variability in oral pheneticillin absorption. We employed an Oral Absorption Test (OAT) for pheneticillin to identify patients in whom oral pheneticillin absorption is poor. Out of 84 patients 30 patients (36%) were identified as insufficient absorbers. Treatment failure due to pheneticillin malabsorption can be avoided by performing an OAT, and these patients should be treated by another antibiotic, which is known to be absorbed well. Keywords: penicillin; oral; pheneticillin; streptococcal 1. Background In the Netherlands, patients with severe streptococcal infections are effectively treated with narrow-spectrum antibiotics, most frequently with initial intravenous (iv) penicillin G followed by oral maintenance therapy, usually with pheneticillin. The advantages of this treatment approach are the bactericidal activity of penicillin, the low costs, the possibility to switch to an oral antibiotic as soon as possible, and the lower risk of introducing resistance associated with narrow-spectrum antibiotics.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Title Antimicrobial Therapy for Acute Cholecystitis: Tokyo Guidelines
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by HKU Scholars Hub Title Antimicrobial therapy for acute cholecystitis: Tokyo Guidelines Yoshida, M; Takada, T; Kawarada, Y; Tanaka, A; Nimura, Y; Gomi, H; Hirota, M; Miura, F; Wada, K; Mayumi, T; Solomkin, JS; Author(s) Strasberg, S; Pitt, HA; Belghiti, J; de Santibanes, E; Fan, ST; Chen, MF; Belli, G; Hilvano, SC; Kim, SW; Ker, CG Journal Of Hepato-Biliary-Pancreatic Surgery, 2007, v. 14 n. 1, p. Citation 83-90 Issued Date 2007 URL http://hdl.handle.net/10722/84203 Rights J Hepatobiliary Pancreat Surg (2007) 14:83–90 DOI 10.1007/s00534-006-1160-y Antimicrobial therapy for acute cholecystitis: Tokyo Guidelines Masahiro Yoshida1, Tadahiro Takada1, Yoshifumi Kawarada2, Atsushi Tanaka3, Yuji Nimura4, Harumi Gomi5, Masahiko Hirota6, Fumihiko Miura1, Keita Wada1, Toshihiko Mayumi7, Joseph S. Solomkin8, Steven Strasberg9, Henry A. Pitt10, Jacques Belghiti11, Eduardo de Santibanes12, Sheung-Tat Fan13, Miin-Fu Chen14, Giulio Belli15, Serafin C. Hilvano16, Sun-Whe Kim17, and Chen-Guo Ker18 1 Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan 2 Mie University School of Medicine, Mie, Japan 3 Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan 4 Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan 5 Division of Infection Control and Prevention, Jichi Medical University Hospital, Tochigi, Japan 6 Department of Gastroenterological
    [Show full text]
  • Consideration of Antibacterial Medicines As Part Of
    Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee on Selection and Use of Essential Medicines (see The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO: https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1) and Corrigenda (March 2020) – TRS1021 (https://www.who.int/medicines/publications/essentialmedicines/TRS1021_corrigenda_March2020. pdf?ua=1). Executive summary of the report: https://apps.who.int/iris/bitstream/handle/10665/325773/WHO- MVP-EMP-IAU-2019.05-eng.pdf?ua=1.
    [Show full text]
  • Cyslabdan, a New Potentiator of Imipenem Activity Against Methicillin-Resistant Staphylococcus Aureus, Produced by Streptomyces Sp
    J. Antibiot. 61(1): 7–10, 2008 THE JOURNAL OF ORIGINAL ARTICLE ANTIBIOTICS Cyslabdan, a New Potentiator of Imipenem Activity against Methicillin-resistant Staphylococcus aureus, Produced by Streptomyces sp. K04-0144 II. Biological Activities Atsushi Fukumoto, Yong-Pil Kim, Hideaki Hanaki, Kazuro Shiomi, Hiroshi Tomoda, Satoshi O¯ mura Received: October 5, 2007 / Accepted: December 4, 2007 © Japan Antibiotics Research Association Abstract Cyslabdan produced by Streptomyces sp. K04- 0144 was found to potentiate imipenem activity against methicillin-resistant Staphylococcus aureus (MRSA). The MIC value of imipenem against MRSA was reduced from 16 to 0.015 mg/ml in combination with cyslabdan. Study on anti-MRSA activity of other typical antibiotics in combination with cyslabdan showed that the potentiating activity was limited to b-lactam antibiotics. Furthermore, among b-lactam antibiotics, the activity of carbapenems Fig. 1 Structure of cyslabdan. was most remarkably poteintiated by cyslabdan. Keywords cyslabdan, imipenem potentiator, cyslabdan including potentiation of imipenem activity methicillin-resistant Staphylococcus aureus, MRSA, against MRSA are described. Streptomyces sp. K04-0144, b-lactam Materials and Methods Introduction Materials During our screening for potentiators of imipenem activity The following materials were purchased from commercial against methicillin-resistant Staphylococcus aureus sources: Cloxacillin (ICN Biomedicals), ampicillin (Wako), (MRSA) from microbial metabolites, cyslabdan (Fig. 1) cefalexin (Wako), cefazolin (Wako), ciprofloxacin (Wako), was isolated from the culture broth of Streptomyces sp. vancomycin (Wako), tetracycline (Wako), biapenem (Meiji K04-0144. The compound has a labdane-type diterpene Seika), streptomycin (Meiji Seika), meropenem (Sumitomo skeleton connecting with an N-acetylcysteine via thioether Pharmaceuticals), panipenem (Sankyo), penicillin G linkage [1]. In this study, the biological activities of (Sigma), cefotaxime (Sigma), cefmetazole (Sigma), and S.
    [Show full text]